Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITIL-168 with Pembrolizumab in Advanced Solid Tumors
NCT05393635Phase 1Withdrawn
- Sponsor
- Instil Bio, Inc.
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
01
Overview
Phase 1, open-label trial of ITIL-168 in Cervical Cancer (CC), head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Instil Bio, Inc. Primary endpoint: Frequency and severity of ITIL-168 treatment-emergent adverse events up to 24 months. Planned start Aug 2022; status: withdrawn.
02
Drugs
ITIL-168
03
Conditions
Cervical Cancer (CC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05393635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393635.